Does Rallies show 13F holders for ORIC?

Yes. Rallies tracks hedge fund and 13F ownership data for ORIC, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ORIC research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ORIC. It does not provide personalized investment advice.

ORIC (Oric Pharmaceuticals, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Oric Pharmaceuticals, Inc. Common Stock (ORIC) is a publicly traded Healthcare sector company. As of May 21, 2026, ORIC trades at $8.47 with a market cap of $820.89M and a P/E ratio of -5.61. ORIC moved +5.52% today. Year to date, ORIC is +3.19%; over the trailing twelve months it is +48.32%. Its 52-week range spans $3.90 to $14.93. Analyst consensus is strong buy with an average price target of $20.89. Rallies surfaces ORIC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ORIC stock?

Hedge funds tracked by Rallies that own ORIC include Viking Global, Orbimed Advisors, and Redmile Group. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Oric Pharmaceuticals, Inc. Common Stock.

ORIC Key Metrics

Key financial metrics for ORIC
Metric	Value
Price	$8.47
Market Cap	$820.89M
P/E Ratio	-5.61
EPS	$-1.47
Dividend Yield	0.00%
52-Week High	$14.93
52-Week Low	$3.90
Volume	664.75K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-129.47M
Gross Margin	0.00%

Top Hedge Funds Holding ORIC

Viking Global holds 5.82M shares of ORIC, changed -11.38% as of Mar 31, 2026.
Orbimed Advisors holds 2.69M shares of ORIC, changed -26.03% as of Mar 31, 2026.
Redmile Group holds 415.71K shares of ORIC, changed -7.23% as of Mar 31, 2026.

Latest ORIC News

ORIC selects 400 mg rinzimetostat dose for Phase 3 after 93% rPFS; $420M runway — May 4, 2026
Rinzimetostat Inhibits PRC2 in Over 1,100 Samples, Enhances CSPC/CRPC Response — Apr 17, 2026
ORIC selects 400 mg RP3D of rinzimetostat, shows 84% five-month rPFS — Mar 31, 2026
ORIC’s Rinzimetostat Shows Best-in-Class Preclinical Efficacy in Resistant Prostate Cancer Models — Mar 17, 2026
JPMorgan Maintains Overweight on Oric Citing 55% PSA50 Response and Phase 3 Timeline — Mar 10, 2026

Recent ORIC Insider Trades

Piscitelli Dominic sold 52.00K (~$702.69K) on Feb 24, 2026.
Heyman Richard A. sold 3.50K (~$42.02K) on Jan 16, 2026.
Heyman Richard A. sold 3.20K (~$38.41K) on Jan 16, 2026.

ORIC Analyst Consensus

11 analysts cover ORIC: 0 strong buy, 11 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $20.89.

Common questions about ORIC

Who owns ORIC stock?: Hedge funds tracked by Rallies that own ORIC include Viking Global, Orbimed Advisors, and Redmile Group. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Oric Pharmaceuticals, Inc. Common Stock.
Does Rallies show 13F holders for ORIC?: Yes. Rallies tracks hedge fund and 13F ownership data for ORIC, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ORIC research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ORIC. It does not provide personalized investment advice.